CD25+CD44+ DN2 cells stained with an anti-BrdU detection antibody indicated that there was a modest decrease in total BrdU+ thymic cells in tumor progressors; however, proliferation amongst BrdU+ DN2 cells remained unchanged in control vs. tumor-bearing mice (Figure 2A). The gene discussed is CD44; the disease is neoplasm.